Centice Corporation Selected to Participate in National Institutes of Health (NIH) Commercial Assistance Program (CAP)

Company selected into program to bring commercial viability for Coded Aperture Spectroscopy in analysis and quantification of cardiac biomarkers

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
We are excited to engage with the healthcare industry to see where our technology can be applied in saving lives

Morrisville, NC (PRWEB) November 10, 2011

Centice Corporation, a pioneer in Coded Aperture Raman Spectroscopy and Hyper Spectral Imaging, announced today the selection of the company to participate in NIH’s Commercial Assistance Program. The NIH program is designed to assist SBIR Phase II companies who have demonstrated promising new technologies with additional resources, strategic planning expertise and broader industry exposure. Centice was the recipient of an SBIR Phase II grant in 2009. The grant was awarded to apply Coded Aperture Spectroscopy in analyzing key cardiac biomarkers in a Lateral Flow Immunoassay (LFI).

Coded Aperture spectroscopic design provides a number of advantages that were seen as necessary for better determination of cardiac events. Measuring cardiac biomarkers is faster, more reliable and less costly with Coded Aperture Design than with existing LFI reader technologies. Coded Aperture Raman Spectroscopy yields more data from a larger field of view than conventional pinhole or slit aperture designs.

“We are excited to engage with the healthcare industry to see where our technology can be applied in saving lives” said Centice CEO, Dr. Prasant Potuluri. “The grant proved there is significant value in more effectively measuring biomarkers in next generation LFI solutions.”

The poster accompanying the scientific paper presentation is available on the Centice website at http://www.centice.com under the Knowledge Center.

About Centice

Centice Corporation creates and delivers advanced sensor technologies and products to select markets in pharmaceutical development, biotechnology, healthcare, process manufacturing and homeland security. With patented Coded Aperture designs and an expertise in sensor fusion engineering, the company leads the market in low cost advantages, measurement reliability, and unsurpassed data acquisition area size. Centice’s scientists and engineering teams provide mechanical and electrical professional services to support a network of partners and integrators building sophisticated sensor solutions. Leading edge science continues to be developed in hyper spectral imaging, spectrometer design, advanced software architectures and chemometrics and compressively sampled spectrometry. Headquartered in Morrisville, N.C. and founded in 2004, the company markets products directly and through distributors. More information can be found at http://www.centice.com.

###


Contact